Fenwick & West represented Loxo Oncology, Inc. (NAS: LOXO), a biopharmaceutical company focused on targeted cancer therapies, in its underwritten public offering of 1,926,250 shares of its common stock for gross proceeds of approximately $41 million. The offering was made pursuant to an effective shelf registration statement previously filed with the SEC.
Citigroup and Cowen and Company acted as joint book-running managers and Stifel acted as joint lead manager for the offering.
The Fenwick transaction team included corporate partners Effie Toshav and Robert Freedman and associates Julia Forbess, Jordan Roberts and Can Sun.